HIMS — Hims & Hers Health, Inc.

—
NYSE · Health Care · Health Care Providers & Services · CIK 1773751 ·
Last close
$17.55
Market Cap
$3.97B
52W High
$40.99
52W Low
$13.74
ADV30
14,068,557
Next earnings
2026-11-09
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 890,373,000 509,199,000 -66,146,000 -33,040,000 3,546,862,000 605,604,000 3,191,565,000
Jun 2026 753,214,000 480,803,000 -97,192,000 -86,290,000 3,628,814,000 609,811,000 3,304,742,000
Mar 2026 608,104,000 396,787,000 -78,323,000 -92,115,000 2,267,043,000 222,266,000 1,820,876,000
Dec 2025 617,818,000 444,435,000 9,186,000 20,601,000 2,154,705,000 228,616,000 1,613,777,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$180,122,000
Investing CF
$-70,008,000
Financing CF
$147,430,000
CapEx
$-171,878,000
Dividends Paid
—
Buybacks
$-89,960,000
EPS Diluted TTM
$-0.83
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-325,217,000
Inventory
$107,848,000
Receivables
$427,847,000
ST Investments
$106,617,000
EBIT TTM
$-232,475,000
Pretax Income TTM
$-222,081,000
Interest Exp TTM
—
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,869,509,120
EBITDA
$-75,537,000
Free Cash Flow
$573,203,392
Enterprise Value
$5,473,491,968
Total Cash
$712,220,992
Total Debt
$1,560,755,968
Shares Out
226,034,799
Trailing EPS
$-0.83
Book Value
$1.52
ROE
-40.8%
ROA
-4.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,347,637,000 105,613,000 128,365,000 2,154,705,000 1,613,777,000 540,928,000 300,006,000
Dec 2024 1,476,514,000 61,903,000 126,038,000 707,539,000 230,823,000 476,716,000 251,084,000
Dec 2023 872,000,000 -29,453,000 -23,546,000 441,186,000 97,157,000 344,029,000 73,483,000
Dec 2022 526,916,000 -68,697,000 -65,678,000 366,341,000 54,600,000 311,741,000 -26,531,000

TTM Snapshot

Revenues TTM
$2,578,112,000
NetIncome TTM
$-142,030,000
OpCashFlow TTM
—
Assets (Latest)
$3,628,814,000
Forward EPS
$0.40

Max Pain — expiry 2026-11-27

max pain strike: $21.00 · spot: $17.05 · call oi: 12,166 · put oi: 6,642
Expected Move to 2026-11-27: ±$1.58 (9.27%) — implied range $15.47 – $18.63 · ATM straddle on $17.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CDNA CareDx, Inc. $3.92B $74.56 —
BLLN BillionToOne, Inc. $4.22B $97.50 —
ACHC Acadia Healthcare Company, Inc. $3.53B $37.94 —
SGRY Surgery Partners, Inc. $3.51B $26.85 —
SHC Sotera Health Co $4.58B $16.05 —

News headlines (Yahoo Finance, 1h cache)

Hims Is Getting into Peptides
2026-11-18 17:43 · Yahoo
Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health
2026-11-18 14:00 · Yahoo
Hims & Hers Stock Fell 32% As Profit Slipped
2026-11-17 14:13 · Yahoo
Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy?
2026-11-16 18:56 · Yahoo
Hims & Hers Lost 100K Subscribers Before Adding Eli Lilly’s $299 Zepbound: Buy the Dip, or Wait?
2026-11-16 09:28 · Yahoo
LifeStance, Private Equity Rollup Turned Organic Growth Stock, Targets A Profound Void
2026-11-13 21:19 · Yahoo
Should Hims & Hers Stock's Drop After Earnings Worry You?
2026-11-13 20:23 · Yahoo
Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?
2026-11-13 18:00 · Yahoo
HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs
2026-11-13 15:12 · Yahoo
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
2026-11-13 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.